Lineage Cell Therapeutics
LCTX
LCTX
56 hedge funds and large institutions have $63.8M invested in Lineage Cell Therapeutics in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
3% less funds holding
Funds holding: 58 → 56 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
69% less call options, than puts
Call options by funds: $202K | Put options by funds: $654K
Holders
56
Holding in Top 10
1
Calls
$202K
Puts
$654K
Top Buyers
| 1 | +$460K | |
| 2 | +$320K | |
| 3 | +$165K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$117K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$116K |
Top Sellers
| 1 | -$252K | |
| 2 | -$142K | |
| 3 | -$76K | |
| 4 |
Charles Schwab
San Francisco,
California
|
-$74.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$54K |